Streetbeat News

CHRO

Chromocell Therapeutics Corporation

Industry

Biotechnology

Chromocell Therapeutics Corporation, a clinical-stage biotech company, focuses on the discovery, development, and commercialization of new therapeutics to alleviate pain. The company intends to selectively target the sodium ion-channel known as NaV1.7, as well as other receptors in the NaV family. Its lead compound comprises CC8464, which is in Phase 2a clinical trials for use in the treatment of erythromelalgia, as well as other fields of neuropathic pain. Chromocell Therapeutics Corporation was founded in 2002 and is based in Freehold, New Jersey.

Open

0.69

Mkt cap

3.6M

Volume

13K

High

0.69

P/E Ratio

-0.38

52-wk high

6.00

Low

0.63

Div yield

N/A

52-wk low

0.52

In Thursday's after-market session, several health care stocks experienced significant price movements. Notable gainers included Cardio Diagnostics Holdings, TC BioPharm, and Seres Therapeutics, while Cue Biopharma and enVVeno Medical were among the biggest losers.

Portfolio Pulse from Benzinga Insights

September 26, 2024 | 8:31 pm

Chromocell Therapeutics has announced a $250,000 stock repurchase plan, which represents 23% of its non-affiliate float. The Board of Directors has authorized the plan with the flexibility to modify or terminate it.

Portfolio Pulse from Benzinga Newsdesk

August 07, 2024 | 12:45 pm

Alliance Global Partners has initiated coverage on Chromocell Therapeutics with a Buy rating, as announced by analyst James Molloy.

Portfolio Pulse from Benzinga Newsdesk

June 18, 2024 | 5:28 pm

The article highlights significant intraday movements in health care stocks on Wednesday. Notable gainers include Innovative Eyewear (LUCY), Reshape Lifesciences (RSLS), Sonoma Pharmaceuticals (SNOA), Apollomics (APLM), Onconetix (ONCO), and Chromocell Therapeutics (CHRO). Significant losers include TransCode Therapeutics (RNAZ), Cue Health (HLTH), Sharps Technology (STSS), Maravai LifeSciences (MRVI), Genetic Technologies (GENE), and Biohaven (BHVN).

Portfolio Pulse from Benzinga Insights

May 29, 2024 | 4:31 pm

Health care stocks showed significant movement in Monday's intraday session, with notable gainers including CareCloud, Novavax, and Macrogenics, and losers like TransCode Therapeutics and Applied DNA Sciences. Earnings reports influenced several stock movements.

Portfolio Pulse from Benzinga Insights

May 13, 2024 | 4:31 pm

Super Micro Computer, Inc. (SMCI) shares fell by 13.2% after the company announced its third-quarter earnings date without providing preliminary estimates, unlike the previous quarter. Other stocks showed significant movement, with notable gainers including Next.e.GO N.V. (EGOX) and Redwoods Acquisition Corp. (RWOD), and losers like Sunshine Biopharma, Inc. (SBFM) and iSpecimen Inc. (ISPC).

Portfolio Pulse from Avi Kapoor

April 19, 2024 | 5:25 pm

In Friday's pre-market session, several healthcare stocks showed significant movement. Chromocell Therapeutics, Kineta, Portage Biotech, Erasca, MSP Recovery, and Cue Health were among the gainers, with increases ranging from 12.25% to 21.6%. On the downside, Nexalin Technology, iSpecimen, INVO Bioscience, Intelligent Bio Solutions, Trevena, and PaxMedica experienced declines between 9.58% and 18.4%. Notably, MSP Recovery and INVO Bioscience had recent earnings reports influencing their stock movements.

Portfolio Pulse from Benzinga Insights

April 19, 2024 | 12:08 pm

Travelers Companies, Inc. (TRV) shares fell by 8.1% after reporting mixed Q1 earnings, missing the consensus forecast. Other stocks showed significant movement, with INVO Bioscience, Inc. (INVO) and Edible Garden AG (EDBL) among the top gainers, while ICZOOM Group Inc. (IZM) and Sunshine Biopharma, Inc. (SBFM) led the losers. The market saw a wide range of stock performance, influenced by earnings reports, strategic agreements, and analyst ratings.

Portfolio Pulse from Avi Kapoor

April 17, 2024 | 5:36 pm

In Wednesday's pre-market session, health care stocks saw significant movements. INVO Bioscience led the gainers with a 93.4% increase following their Q4 earnings release. Other notable gainers include Clene, Galera Therapeutics, Vanda Pharma, Chromocell Therapeutics, and BIMI Intl Medical. On the losing side, Sage Therapeutics saw the largest drop of 19.4%, followed by declines in Ontrak, China SXT Pharmaceuticals, Dynatronics, Etao International Co, and Precision BioSciences.

Portfolio Pulse from Benzinga Insights

April 17, 2024 | 12:08 pm

INVO Bioscience shares surged 73% in pre-market trading after reporting a 397% increase in quarterly revenue. Other stocks also showed significant movement in pre-market trading, with notable gainers including Mobile Global Esports, Chromocell Therapeutics, and Clene Inc., and losers like Connexa Sports Technologies and Dynatronics Corporation.

Portfolio Pulse from Avi Kapoor

April 17, 2024 | 10:13 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.